3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Endocrine
1
Conditions
Endometrial Neoplasms
6
Neoplasms
5
Colonic Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Uterine Cervical Neoplasms
2
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
1
Penile Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ovarian Carcinosarcoma
1
Neoplasms, Second Primary
1
Locally Advanced Rectal Cancer (LARC)
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Carcinoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Adrenocortical Carcinoma
1
Interventions
pembrolizumab
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
cemiplimab
2
camrelizumab
2
cabozantinib
2
apatinib
2
Mitotane
2
fludarabine phosphate
1
dostarlimab
1
Megestrol Acetate
1
Interleukin-13
1
Fluorodeoxyglucose F18
1
Floxuridine
1
Etoposide
1
Drug Therapy
1
Doxorubicin
1
Dexamethasone
1
Cyclophosphamide
1
Cisplatin
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Adrenocortical Carcinoma
×
dostarlimab
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled